Your browser doesn't support javascript.
loading
The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy.
Kinahan, Paul E; Perlman, Eric S; Sunderland, John J; Subramaniam, Rathan; Wollenweber, Scott D; Turkington, Timothy G; Lodge, Martin A; Boellaard, Ronald; Obuchowski, Nancy A; Wahl, Richard L.
Afiliação
  • Kinahan PE; From the Department of Radiology, University of Washington, 1959 NE Pacific St, RR215, Box 357115, Seattle, WA 98195-7117 (P.E.K.); Perlman Advisory Group, LLC, Hillsdale, NY (E.S.P.); Department of Radiology, University of Iowa, Iowa City, Iowa (J.J.S.); Department of Radiology, University of Texas
  • Perlman ES; From the Department of Radiology, University of Washington, 1959 NE Pacific St, RR215, Box 357115, Seattle, WA 98195-7117 (P.E.K.); Perlman Advisory Group, LLC, Hillsdale, NY (E.S.P.); Department of Radiology, University of Iowa, Iowa City, Iowa (J.J.S.); Department of Radiology, University of Texas
  • Sunderland JJ; From the Department of Radiology, University of Washington, 1959 NE Pacific St, RR215, Box 357115, Seattle, WA 98195-7117 (P.E.K.); Perlman Advisory Group, LLC, Hillsdale, NY (E.S.P.); Department of Radiology, University of Iowa, Iowa City, Iowa (J.J.S.); Department of Radiology, University of Texas
  • Subramaniam R; From the Department of Radiology, University of Washington, 1959 NE Pacific St, RR215, Box 357115, Seattle, WA 98195-7117 (P.E.K.); Perlman Advisory Group, LLC, Hillsdale, NY (E.S.P.); Department of Radiology, University of Iowa, Iowa City, Iowa (J.J.S.); Department of Radiology, University of Texas
  • Wollenweber SD; From the Department of Radiology, University of Washington, 1959 NE Pacific St, RR215, Box 357115, Seattle, WA 98195-7117 (P.E.K.); Perlman Advisory Group, LLC, Hillsdale, NY (E.S.P.); Department of Radiology, University of Iowa, Iowa City, Iowa (J.J.S.); Department of Radiology, University of Texas
  • Turkington TG; From the Department of Radiology, University of Washington, 1959 NE Pacific St, RR215, Box 357115, Seattle, WA 98195-7117 (P.E.K.); Perlman Advisory Group, LLC, Hillsdale, NY (E.S.P.); Department of Radiology, University of Iowa, Iowa City, Iowa (J.J.S.); Department of Radiology, University of Texas
  • Lodge MA; From the Department of Radiology, University of Washington, 1959 NE Pacific St, RR215, Box 357115, Seattle, WA 98195-7117 (P.E.K.); Perlman Advisory Group, LLC, Hillsdale, NY (E.S.P.); Department of Radiology, University of Iowa, Iowa City, Iowa (J.J.S.); Department of Radiology, University of Texas
  • Boellaard R; From the Department of Radiology, University of Washington, 1959 NE Pacific St, RR215, Box 357115, Seattle, WA 98195-7117 (P.E.K.); Perlman Advisory Group, LLC, Hillsdale, NY (E.S.P.); Department of Radiology, University of Iowa, Iowa City, Iowa (J.J.S.); Department of Radiology, University of Texas
  • Obuchowski NA; From the Department of Radiology, University of Washington, 1959 NE Pacific St, RR215, Box 357115, Seattle, WA 98195-7117 (P.E.K.); Perlman Advisory Group, LLC, Hillsdale, NY (E.S.P.); Department of Radiology, University of Iowa, Iowa City, Iowa (J.J.S.); Department of Radiology, University of Texas
  • Wahl RL; From the Department of Radiology, University of Washington, 1959 NE Pacific St, RR215, Box 357115, Seattle, WA 98195-7117 (P.E.K.); Perlman Advisory Group, LLC, Hillsdale, NY (E.S.P.); Department of Radiology, University of Iowa, Iowa City, Iowa (J.J.S.); Department of Radiology, University of Texas
Radiology ; 294(3): 647-657, 2020 03.
Article em En | MEDLINE | ID: mdl-31909700
ABSTRACT
The Quantitative Imaging Biomarkers Alliance (QIBA) Profile for fluorodeoxyglucose (FDG) PET/CT imaging was created by QIBA to both characterize and reduce the variability of standardized uptake values (SUVs). The Profile provides two complementary claims on the precision of SUV measurements. First, tumor glycolytic activity as reflected by the maximum SUV (SUVmax) is measurable from FDG PET/CT with a within-subject coefficient of variation of 10%-12%. Second, a measured increase in SUVmax of 39% or more, or a decrease of 28% or more, indicates that a true change has occurred with 95% confidence. Two applicable use cases are clinical trials and following individual patients in clinical practice. Other components of the Profile address the protocols and conformance standards considered necessary to achieve the performance claim. The Profile is intended for use by a broad audience; applications can range from discovery science through clinical trials to clinical practice. The goal of this report is to provide a rationale and overview of the FDG PET/CT Profile claims as well as its context, and to outline future needs and potential developments.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fluordesoxiglucose F18 / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada / Neoplasias Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Radiology Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fluordesoxiglucose F18 / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada / Neoplasias Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Radiology Ano de publicação: 2020 Tipo de documento: Article